Posted by Social Science Research Network
Pleading Standards: The Hidden Threat to Actavis Michael A. Carrier (Rutgers University)
Abstract: In FTC v. Actavis, the Supreme Court held that a brand drug company’s payment to a generic firm to settle patent litigation and delay entering the market could violate the antitrust laws.
Since the decision, the issue of the pleading requirements imposed on plaintiffs has slipped under the radar. Along those lines, it is concerning that courts recently have imposed unprecedented hurdles. For example, the court in In re Effexor XR Antitrust Litigation failed to credit allegations that a generic delayed entering the market because a brand promised not to introduce its own “authorized generic” that would have dramatically reduced the true generic’s revenues. The same judge, in In re Lipitor Antitrust Litigation, dismissed a complaint despite allegations that the generic delayed entry in return for the brand’s forgiveness of hundreds of millions of dollars in potential damages in separate litigation.
This Essay explains why the excessive pleading standards in Effexor and Lipitor are not consistent with Actavis or the leading caselaw on pleading. It discusses cases that apply a more justifiable analysis. And it concludes that the imposition of inappropriate pleading standards significantly weakens the antitrust analysis of potentially anticompetitive settlements.
Featured News
Court Order Temporarily Halts U.S. Consumer Financial Protection Bureau Layoffs
Feb 16, 2025 by
CPI
Nokia Poised to Gain EU Approval for $2.3 Billion Infinera Acquisition
Feb 16, 2025 by
CPI
Turkey Fines Frito-Lay in Antitrust Crackdown
Feb 16, 2025 by
CPI
Advances Bill to Strengthen Antitrust Enforcement Through AI
Feb 16, 2025 by
CPI
Intel Faces Potential Breakup as Broadcom and TSMC Explore Deals
Feb 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon